Innate Pharma announces abstracts selected for ESMO congress 2023

• Sanofi’s ongoing SAR’579/IPH6101 Phase 1/2 trial in hematologic malignancies selected for oral presentation 

• Presentations under the AstraZeneca collaboration include an IPH5201 early lung cancer Trial in Progress poster and monalizumab SCCHN updates 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place October 20-24 in Madrid, Spain.

Abstract details: 

SAR’579 / IPH6101 (from a Joint Research Collaboration with Sanofi)

Presentation Number: 823O
Presentation Title: Preliminary Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the CD123 NK Cell Engager (NKCE) SAR443579 in Patients (pts) with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)
Speaker: Mojca Jongen-Lavrencic (Rotterdam, Netherlands)
Session Type/Title: Oral Session: Proffered Paper Session / Hematologic Malignancies
Session Date and Time: Sun, 22.10.2023 16:30 – 18:00

IPH5201 (AstraZeneca collaboration)

Abstract: 1290TiP
Abstract Title: A Phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE)
Speaker: Fabrice Barlesi (Villejuif, France)
Session Type/Title: Poster Session:  NSCLC, early stage
Onsite Poster display date: Sat, 21.10.2023

Monalizumab (AstraZeneca collaboration; ISS)

Abstract: 935P 
Abstract Title: A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Speaker: Rachel Galot (Woluwe-Saint-Lambert, Belgium)
Session Type/Title: Poster Session:  Head and neck cancers, excl. thyroid
Onsite Poster display date: Sun, 22.10.2023

Monalizumab (AstraZeneca collaboration)

Presentation Number: 854O
Presentation Title: INTERLINK-1: Phase 3 study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
Speaker: Jérôme Fayette (Lyon, France)
Session Type/Title: Oral Session: Proffered Paper Session / Head and neck cancer
Session Date and Time: Mon, 23.10.2023 08:30 – 10:00